Table 2.

Normal tissue tracer uptake as percent of injected dose per kilogram bodyweight per ⁸⁹Zr-monocloncal antibody tracer 4 days post tracer injection.

Tissue	VOI (%ID/kg, ±SD)
	89Zr-lumretuzumab	89Zr-MMOT0530A	89Zr-bevacizumab	89Zr-trastuzumab	ANOVA/Kruskal-Wallis P
Aorta	6.2 (± 1.6)	7.5 (± 1.3)	7.1 (± 1.6)	7.7 (± 2.8)	0.35
Bone marrow	1.9 (± 0.6)	2.9 (± 0.5)	2.1 (± 0.7)	2.8 (± 1.0)	0.02 a
Brain	0.1 (± 0.1)	0.3 (± 0.2)	0.2 (± 0.1)	0.3 (± 0.1)	0.09
Compact bone	0.9 (± 0.6)	1.2 (± 0.3)	0.6 (± 0.2)	0.8 (± 0.4)	0.01 b
Fat tissue	0.2 (± 0.1)	0.2 (± 0.1)	0.2 (± 0.2)	0.3 (± 0.1)	0.26
Intestine	3.4 (± 1.5)	3.9 (± 1.5)	2.7 (± 1.5)	5.4 (± 2.4)	0.02 c
Kidney	5.4 (± 0.6)	7.6 (± 1.6)	6.1 (± 1.1)	8.7 (± 1.5)	<0.01 d
Liver	7.3 (± 1.3)	10.8 (± 3.6)	9.9 (± 1.4)	6.8 (± 1.6)	<0.01 e
Lung	1.1 (± 0.1)	1.7 (± 0.7)	1.1 (± 0.2)	1.4 (± 0.4)	0.02 a
Muscle	0.7 (± 0.2)	0.8 (± 0.2)	0.7 (± 0.2)	0.8 (± 0.3)	0.36
Spleen	5.0 (± 1.2)	5.8 (± 1.8)	4.6 (± 0.8)	5.1 (± 1.6)	0.32

VOI, Volume of interest. a, Post hoc analysis showed no significant difference between the four groups. b, Significant difference between ⁸⁹Zr-MMOT0530A and ⁸⁹Zr-bevacizumab. c, Significant difference between ⁸⁹Zr-bevacizumab and ⁸⁹Zr-trastuzumab. d, Significant difference between ⁸⁹Zr-lumretuzumab and ⁸⁹Zr-MMOT0530A, ⁸⁹Zr-lumretuzumab and ⁸⁹Zr-trastuzumab, ⁸⁹Zr-bevacizumab and ⁸⁹Zr-trastuzumab, and ⁸⁹Zr-MMOT0530A. e, Significant difference between ⁸⁹Zr-lumretuzumab and ⁸⁹Zr-bevacizumab, ⁸⁹Zr-bevacizumab and ⁸⁹Zr-trastuzumab, and ⁸⁹Zr-trastuzumab and ⁸⁹Zr-MMOT0530A.